The US pharmaceutical industry has called for the reversal of a judicial ruling that could withdraw regulatory approval for a common abortion drug, arguing that the judgment would diminish the authority of government agencies and put the industry at risk.
An open letter signed by more than 400 senior pharma and biotech executives strongly condemned the ruling last week by Texas federal judge Matthew Kacsmaryk, which if upheld would amount to a nationwide ban on mifepristone.
The drug is one of two commonly used to terminate pregnancies. Together, the pills account for more than half of all abortions in the US.
您已閱讀16%（615字），剩余84%（3314字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。